Rho GTPase-activating protein 1 promotes hepatocellular carcinoma progression via modulation by CircPIP5K1A/MiR-101-3p

被引:1
|
作者
Xu, Yanni [1 ,2 ]
Liu, Xiaodi [3 ,4 ]
Cao, Jincheng [1 ,2 ]
Wu, Ye [1 ,2 ]
Jiang, Qiongchao [1 ]
Luo, Baoming [1 ]
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Ultrasound, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat sen Univ, Sun Yat sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Guangdong, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Ultrasound, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Lab Ultrasound Med, Chengdu 610041, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
carcinogenic factor; hepatology; malignant tumor; non-coding RNAs; oncogene; CELL-PROLIFERATION; MIR-101-3P; EXPRESSION; TARGETS; PATHOGENESIS; APOPTOSIS; MIGRATION; ARHGAP1;
D O I
10.1111/hepr.13972
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AimThere has been an increased focus on regulating cell function with Rho family GTPases, including proliferation, migration/invasion, polarity, and adhesion. Due to the challenges involved in targeting Rho family GTPases directly, it may be more effective to target their regulators, such as Rho GTPase-activating protein 1 (ARHGAP1). This present research was performed to define the clinical significance of ARHGAP1 expression, as well as its regulatory mechanisms in hepatocellular carcinoma.MethodsARHGAP1 and miR-101-3p expression of liver cancer patients, and their relevance with clinicopathological characteristics and prognosis were analyzed by the Cancer Genome Atlas sequencing data, and verified using samples of hepatocellular carcinoma patients. The interactions between miR-101-3p and ARHGAP1 or circPIP5K1A were validated by bioinformatic analyses, as well as confirmed by quantitative reverse transcription polymerase chain reaction, western blotting, and dual-luciferase reporter analysis. Plate clonality assays, cell adhesion and migration experiments, and proliferation experiments were used for assessing the participation of the circPIP5K1A/miR-101-3p/ARHGAP1 pathway in cell proliferation and motility.ResultsElevated ARHGAP1 and reduced miR-101-3p expression are related to poorer survival. MiR-101-3p targets ARHGAP1 to suppress hepatocellular carcinoma cell colony formation and invasion, whereas miR-101-3p inhibitor reverses liver cancer proliferation and metastasis suppression caused by ARHGAP1 knockdown. In addition, circPIP5K1A, which is mainly distributed in the cytosol, showed carcinogenic effects by sponging miR-101-3p, thus regulating ARHGAP1 expression.ConclusionsARHGAP1 serves as an oncogenic gene in liver cancer, and the expression thereof is regulated by circPIP5K1A through sponging miR-101-3p. CircPIP5K1A regulates ARHGAP1 expression by sponging miR-101-3p. CircPIP5K1A and ARHGAP1 are carcinogenic factors in liver cancer. The circPIP5K1A/miR-101-3p/ARHGAP1 axis governs tumor progression in liver cancer.image
引用
收藏
页码:174 / 188
页数:15
相关论文
共 50 条
  • [31] CircPIP5K1A activates KRT80 and PI3K/AKT pathway to promote gastric cancer development through sponging miR-671-5p
    Song, Hu
    Xu, Yixin
    Xu, Teng
    Fan, Ruizhi
    Jiang, Tao
    Cao, Meng
    Shi, Linseng
    Song, Jun
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 126
  • [32] The GTPase-Activating Protein Rga1 Interacts with Rho3 GTPase and May Regulate Its Function in Polarized Growth in Budding Yeast
    He, Fei
    Nie, Wen-Chao
    Tong, Zongtian
    Yuan, Si-Min
    Gong, Ting
    Liao, Yuan
    Bi, Erfei
    Gao, Xiang-Dong
    PLOS ONE, 2015, 10 (04):
  • [33] miR-3677-3p promotes hepatocellular carcinoma progression via inhibiting GSK3β
    Li, Yanfei
    Zhou, Yajie
    Ma, Linlin
    Liu, Dingsheng
    Dai, Zhensheng
    Shen, Junwei
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2020, 52 (12) : 1404 - 1412
  • [34] Secretory Pathway-Dependent Localization of the Saccharomyces cerevisiae Rho GTPase-Activating Protein Rgd1p at Growth Sites
    Lefebvre, Fabien
    Prouzet-Mauleon, Valerie
    Hugues, Michel
    Crouzet, Marc
    Vieillemard, Aurelie
    McCusker, Derek
    Thoraval, Didier
    Doignon, Francois
    EUKARYOTIC CELL, 2012, 11 (05) : 590 - 600
  • [35] miR-106b-5p promotes aggressive progression of hepatocellular carcinoma via targeting RUNX3
    Gu, Hao
    Gu, Shensen
    Zhang, Xinlong
    Zhang, Songjiang
    Zhang, Dongming
    Lin, Junsheng
    Hasengbayi, Saiken
    Han, Wei
    CANCER MEDICINE, 2019, 8 (15): : 6756 - 6767
  • [36] miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a
    Cao, Man-Qing
    You, A-Bin
    Zhu, Xiao-Dong
    Zhang, Wei
    Zhang, Yuan-Yuan
    Zhang, Shi-Zhe
    Zhang, Ke-wei
    Cai, Hao
    Shi, Wen-Kai
    Li, Xiao-Long
    Li, Kang-Shuai
    Gao, Dong-Mei
    Ma, De-Ning
    Ye, Bo-Gen
    Wang, Cheng-Hao
    Qin, Cheng-Dong
    Sun, Hui-Chuan
    Zhang, Ti
    Tang, Zhao-You
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [37] miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a
    Man-Qing Cao
    A-Bin You
    Xiao-Dong Zhu
    Wei Zhang
    Yuan-Yuan Zhang
    Shi-Zhe Zhang
    Ke-wei Zhang
    Hao Cai
    Wen-Kai Shi
    Xiao-Long Li
    Kang-Shuai Li
    Dong-Mei Gao
    De-Ning Ma
    Bo-Gen Ye
    Cheng-Hao Wang
    Cheng-Dong Qin
    Hui-Chuan Sun
    Ti Zhang
    Zhao-You Tang
    Journal of Hematology & Oncology, 11
  • [38] CircZFR promotes hepatocellular carcinoma progression through regulating miR-3619-5p/CTNNB1 axis and activating Wnt/β-catenin pathway
    Tan, Aichun
    Li, Qiongxuan
    Chen, Lizhang
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 661 : 196 - 202
  • [39] ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling
    Xie, Binhui
    Zen, Qinshan
    Wang, Xiaonong
    He, Xiao
    Xie, Yuankang
    Zhang, Zixiang
    Li, Heping
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (05) : 2057 - 2066
  • [40] MiR-101-3p targets the PI3K-AKT signaling pathway via Birc5 to inhibit invasion, proliferation, and epithelial-mesenchymal transition in hepatocellular carcinoma
    Zhu, Wenyuan
    Ni, Qingqiang
    Wang, Zhengjian
    Zhang, Ruxuan
    Liu, Fangfeng
    Chang, Hong
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)